CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $161.03M, lower than 95% of all stocks globally
- PositionGross margin is 1.8%, lower than 95% of its Biotechnology peers (median 67.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.20BTWD161.03M · vs all stocks (USD)
Revenue (TTM)
815.34MTWD25.26M · vs all stocks (USD)
Profit Margin
-53.53%vs Biotechnology peers
Beta
0.3990xvs all stocks
52-Week Change
-35.06%vs all stocks
Market Capitalization
5.20BTWD161.03M · vs all stocks (USD)
Enterprise Value
6.10BTWD188.90M · vs all stocks (USD)
Price to Sales (TTM)
6.21xvs Biotechnology peers
Price to Book (MRQ)
3.41xvs Biotechnology peers
Enterprise to Revenue
7.48xvs Biotechnology peers
Enterprise to EBITDA
-43.40xvs Biotechnology peers
Gross Margin
1.76%vs Biotechnology peers
Profit Margin
-53.53%vs Biotechnology peers
Operating Margin
-55.48%vs Biotechnology peers
Return on Assets (TTM)
-7.20%vs Biotechnology peers
Return on Equity (TTM)
-25.79%vs Biotechnology peers
Revenue (TTM)
815.34MTWD25.26M · vs all stocks (USD)
Revenue per Share (TTM)
3.60TWDUpdated Jul 15, 2026Quarterly Revenue Growth
61.70%vs Biotechnology peers
Gross Profit (TTM)
-161.98MTWD-5.02M · vs all stocks (USD)
EBITDA (TTM)
-140.47MTWD-4.35M · vs all stocks (USD)
Net Income (TTM)
-436.48MTWD-13.53M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
46.70%vs Biotechnology peers
Operating Cash Flow (TTM)
-67.55MTWD-2.09M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-20.17MTWD-625.07K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Jul 15, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
740.24MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
921.65MTWDFY2025 · Dec 31, 2025Gross Profit
-181.41MTWDFY2025 · Dec 31, 2025Operating Income
-405.39MTWD-12.56M · vs all stocks (USD)
Pre-tax Income
-454.11MTWDFY2025 · Dec 31, 2025Income Tax Expense
-5.48MTWDFY2025 · Dec 31, 2025Net Income
-448.63MTWDFY2025 · Dec 31, 2025EBIT
-420.44MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-137.66MTWDFY2025 · Dec 31, 2025Research & Development
75.91MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
148.07MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
3.12MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
33.67MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-375.44MTWDFY2025 · Dec 31, 2025Free Cash Flow
-463.50MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
224.54MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-454.11MTWDFY2025 · Dec 31, 2025Stock-based Compensation
20.13MTWDFY2025 · Dec 31, 2025Other Non-cash Items
30.55MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.37MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
40.36MTWDFY2025 · Dec 31, 2025Capital Expenditures
-88.06MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-10.54MTWDFY2025 · Dec 31, 2025Net Acquisitions
0.00TWDFY2025 · Dec 31, 2025Purchase of Investments
-24.05MTWDFY2025 · Dec 31, 2025Sale of Investments
7.30MTWDFY2025 · Dec 31, 2025Other Investing Activity
-205.00KTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-105.02MTWDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00TWDFY2025 · Dec 31, 2025Long-term Debt Payments
-149.22MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
280.00MTWDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00TWDFY2025 · Dec 31, 2025Net Financing Cash Flow
136.22MTWDFY2025 · Dec 31, 2025Shares Outstanding
207.23MSharesUpdated Jul 15, 2026Float Shares
115.85MSharesUpdated Jul 15, 2026% Held by Insiders
48.20%vs all stocks
% Held by Institutions
0.08%vs all stocks
Total Cash (MRQ)
216.32MTWD6.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.04TWDUpdated Jul 15, 2026Total Debt (MRQ)
1.18BTWD36.67M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7960xvs Biotechnology peers
Current Ratio (MRQ)
0.6240xvs Biotechnology peers
Book Value per Share (MRQ)
7.17TWDUpdated Jul 15, 2026Total Assets
3.26BTWD101.06M · vs all stocks (USD)
Total Current Assets
776.02MTWDFY2025 · Dec 31, 2025Total Liabilities
1.66BTWDFY2025 · Dec 31, 2025Total Non-current Assets
2.49BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
556.13MTWDFY2025 · Dec 31, 2025Total Current Liabilities
1.11BTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
224.54MTWDFY2025 · Dec 31, 2025Other Short-term Investments
1.20MTWDFY2025 · Dec 31, 2025Accounts Receivable
106.27MTWDFY2025 · Dec 31, 2025Inventory
132.89MTWDFY2025 · Dec 31, 2025Accounts Payable
77.47MTWDFY2025 · Dec 31, 2025Short-term Debt
515.76MTWDFY2025 · Dec 31, 2025Other Current Liabilities
1.74MTWDFY2025 · Dec 31, 2025Long-term Debt
556.13MTWDFY2025 · Dec 31, 2025Common Stock (Book)
2.07BTWDFY2025 · Dec 31, 2025Retained Earnings
-540.63MTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.60BTWD49.55M · vs all stocks (USD)
52-Week Low
23.95TWDUpdated Jul 15, 202652-Week High
40.00TWDUpdated Jul 15, 202652-Week Change
-35.06%vs all stocks
Beta
0.3990xvs all stocks
50-Day MA
26.88TWDUpdated Jul 15, 2026200-Day MA
31.41TWDUpdated Jul 15, 2026Avg 10-Day Volume
168.35KSharesUpdated Jul 15, 2026Avg 30-Day Volume
264.22KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-2.17TWDUpdated Jul 15, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 1.8%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 0.02Industry median: 0.67Industry P5: 0.14Peers compared: 261
Current ratio is 0.62×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.62Industry median: 5.64Industry P5: 1.06Peers compared: 261
Financial Health
Altman Z-Score 1.32: grey zoneSignificant
Altman Z-Score: 1.32
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $161.03M, lower than 95% of all stocks globallySignificant
Market cap (USD): 161,031,666.841Global P5: 269,387,740.27
Revenue is $25.26M, lower than 95% of all stocks globallySignificant
Revenue (USD): 25,264,816.632Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Sensorion SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Graphy Inc.
Tier 1ProductionApproval-Gated PipelineRule
Journey Medical Corp
Tier 1ProductionApproval-Gated PipelineRule
Alector Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chill Brands Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
S Biomedics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Asterasys Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EKF Diagnostics Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Yungjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Grinm Advanced Materials Co., Ltd.
1 interpretationWorking Capital Pattern
C-MER Medical Holdings Ltd.
1 interpretationWorking Capital Pattern
Chipotle Mexican Grill, Inc.
1 interpretationWorking Capital Pattern